AG
TEVA icon

Advisor Group’s Teva Pharmaceuticals TEVA Stock Holding History

Advisor Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-10
Closed -$7K – 5230
2018
Q3 		$7K Buy
+10
New +$232 ﹤0.01% 4467

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

Advisor Group's TEVA Position: Q4 2019 in Review

Advisor Group reduced its Teva Pharmaceuticals (TEVA) stake by 16% in Q4 2019, selling an estimated $76.4K and leaving 45,080 shares worth $442K. The position accounts for ﹤0.01% of the portfolio, ranked #1762.

Advisor Group first reported a position in TEVA in Q2 2016 and has held it in 15 quarters since. The position peaked at $1.08M in Q3 2018. 436 funds tracked by Wall St. Rank hold TEVA as of Q4 2019.

  • Advisor Group held 45,080 shares of Teva Pharmaceuticals worth $442K as of Q4 2019.
  • Advisor Group sold 8,559 Teva Pharmaceuticals shares in Q4 2019, an estimated $76.4K.
  • Teva Pharmaceuticals made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #1762 holding.
  • Advisor Group first reported a position in Teva Pharmaceuticals in Q2 2016 and has held it in 15 quarters since.
  • Advisor Group's Teva Pharmaceuticals position peaked at $1.08M in Q3 2018.
  • 436 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.